ClinicalTrials.gg

Program

delandistrogene moxeparvovec

Its studies are mostly in Muscular Dystrophy, Duchenne, led by Sarepta Therapeutics.

Furthest: phase 4, since Apr 2, 20261 company-led study, 1 open or runningNext primary completion: Aug 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sarepta Therapeutics11 open or runningphase 4since Apr 2, 2026Apr 2, 2026Aug 31, 2027phase 4 · NCT07542314

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 2, 2026First study: phase 4 study in Muscular Dystrophy, DuchenneFirst studyNCT07542314 · 20 planned · United States

Ahead

  1. Aug 31, 2027Primary completion: phase 4 study in Muscular Dystrophy, DuchenneNCT07542314

TargetBeta

DMD →read by rule
“Dystrophin exogenous gene”ChEMBL 37, by rule

Other programs on DMD

ProgramCompanyFurthest phaseStudies
delpacibart zotadirsenNovartisphase 33

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07542314Muscular Dystrophy, Duchenne · United States4RecruitingAug 31, 202720

How it is read

Names in the registry

  • “ELEVIDYS”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.